<DOC>
	<DOCNO>NCT00774163</DOCNO>
	<brief_summary>This phase one study assess safety daily dose Lactobacillus reuteri healthy adult Peru . It conduct preliminary study support clinical trial ass safety efficacy Lactobacillus reuteri versus placebo treatment pediatric diarrhea Peru .</brief_summary>
	<brief_title>Safety Lactobacillus Reuteri Healthy Volunteers</brief_title>
	<detailed_description>This phase I blind randomize study safety tolerability Lactobacillus reuteri DSM 17938 give daily period five consecutive day . Upon enrollment subject randomize one two treatment group ratio treatment placebo 2:1 . Subjects randomize receive either : A. Lactobacillus reuteri ( Lr ) : 108 ( 100 million ) organism Lactobacillus reuteri per dose , give daily five-day treatment period corresponds dose closely related L. reuteri ATCC 55730 strain show therapeutic infantile colic . The strain use study ( DSM 17938 ) cure antibiotic resistance plasmid find original BioGaia strain ( L. reuteri ATCC 55730 ) . B . Placebo oil preparation , administer 5 drop oil vehicle use manufacturing Lr suspension , give daily five-day study period ( BioGaia AB , Stockholm , Sweden ) .</detailed_description>
	<criteria>Adults 1865 exclusion criterion Subject male , subject female childbearing potential must negative serum urine pregnancy test result within 48 hour initiate study preparation agree use acceptable method contraception . Acceptable method contraception include depot form progesterone contain therapy intrauterine device ( IUD ) . No enrollment family member household follow present : Another study participant household Pregnancy current breastfeeding household member Presence infant age 6 month live household Presence immune suppress individual use immunosuppressive agent ( corticosteroid , methotrexate ) household member Presence serious congenital anomaly chronic medical condition would contraindicate participation household member , include history gastrointestinal surgery , chronic gastrointestinal illness , abnormal intestinal anatomy , abnormal bowel functionality Allergy penicillin cephalosporins History antibiotic use last 30 day Use probiotic product within past 90 day History diarrheal illness within past 30 day Presence fever preexist adverse event monitor study Positive result serum diagnostic test antibody HIV , Hepatitis B core antigen , Hepatitis C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>probiotic</keyword>
	<keyword>lactobacillus</keyword>
	<keyword>reuteri</keyword>
	<keyword>none ( safety )</keyword>
</DOC>